Concurrent changes in 1H MRS metabolites and antioxidant enzymes in the brain of C57BL/6 mouse short-termly exposed to cuprizone: Possible implications for schizophrenia-Reference-Cited by-同舟云学术

Concurrent changes in 1H MRS metabolites and antioxidant enzymes in the brain of C57BL/6 mouse short-termly exposed to cuprizone: Possible implications for schizophrenia

Published:2014-04 Issue: Volume:69 Page:20-27
ISSN:0197-0186
Container-title:Neurochemistry International
language:en
Short-container-title:Neurochemistry International

Author:

Xuan Yinghua,Yan Gen,Peng Hui,Wu Renhua,Xu Haiyun

Publisher

Elsevier BV

Subject

Cell Biology,Cellular and Molecular Neuroscience

Reference57 articles.

1. Pathogenesis of multiple sclerosis: what can we learn from the cuprizone model;Acs,2012

2. Microarray analysis of postmortem temporal cortex from patients with schizophrenia;Aston;J. Neurosci. Res.,2004

3. Cuprizone [bis (cyclohexylidenehydrazide)] is selectively toxic for mature oligodendrocytes;Bénardais;Neurotox. Res.,2013

4. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress;Berton;Science,2006

5. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy;Bitsch;Am. J. Neuroradiol.,1999

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sulforaphane, an Nrf-2 Agonist, Modulates Oxidative Stress and Inflammation in a Rat Model of Cuprizone-Induced Cardiotoxicity and Hepatotoxicity;Cardiovascular Toxicology;2023-01

2. Extraction of Individual Metabolite Spectrum in Proton Magnetic Resonance Spectroscopy of Mouse Brain Using Deep Learning;Journal of Magnetics;2021-09-30

3. Differential Susceptibility and Vulnerability of Brain Cells in C57BL/6 Mouse to Mitochondrial Dysfunction Induced by Short-Term Cuprizone Exposure;Frontiers in Neuroanatomy;2020-06-09

4. Cognitive disturbances in the cuprizone model of multiple sclerosis;Genes, Brain and Behavior;2020-05-25

5. Five Decades of Cuprizone, an Updated Model to Replicate Demyelinating Diseases;Current Neuropharmacology;2019-01-07